•  
  •  
 

Abstract

Background: Psoriasis affects approximately 2% of the global population and is associated with comorbidities such as depression, psoriatic arthritis, and cardiometabolic syndrome. Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for moderate-to-severe plaque psoriasis. This study assessed the real-world effectiveness of secukinumab over 52 weeks.

Methods: This retrospective cohort study included 53 patients aged ≥18 years who received secukinumab and were followed for 52 weeks. Patients received weekly loading doses followed by maintenance injections every four weeks. Effectiveness was evaluated using changes in the Psoriasis Area and Severity Index (PASI).

Results: At week 16, 86.8% of patients achieved PASI <5, 79.2% PASI <3, 69.8% PASI <2, and 64.2% PASI <1, indicating substantial improvement. PASI 75 was achieved by 77.4% of patients at week 8. PASI 90 was achieved by 71.7% of all patients and by 76.9% of patients with psoriatic arthritis at week 16. No patients discontinued treatment because of adverse events.

Conclusion: Secukinumab was effective and well-tolerated in this real-world cohort of patients with moderate-to-severe plaque psoriasis, with rapid achievement of PASI 75 by week 8 and a high rate of PASI 90 response by week 16. Longer-term effectiveness beyond these early time points should be interpreted with caution because follow-up at later visits was limited.

References

  1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945–60.
  2. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modeling study. BMJ. 2020;369:1–15.
  3. Steinzor P. Autoimmune diseases prevalent among patients with psoriasis, study finds [Internet]. American Journal of Managed Care; [reviewed 2024 Jun 21; cited 2025 Jul 4]. Available from: https://www.ajmc.com/view/autoimmune-diseases-prevalent-among-patients-with-psoriasis-study-finds
  4. Gisondi P, Rovaris M, Piaserico S, Girolomoni G. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2020;182(1):175–9.
  5. Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment – A meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174–85.
  6. Christensen TE, Callis KP, Papenfuss J, et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol. 2006;126(11):2397–403.
  7. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906.
  8. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.
  9. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:1–17.
  10. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
  11. Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571–9.
  12. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60–9.
  13. Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018;35(2):170–81.
  14. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–70.
  15. Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021;397(10281):1301–15.
  16. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10–5.
  17. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–14.
  18. Badan Pengawas Obat dan Makanan. Fraizeron (secukinumab) [Internet]. Jakarta: Badan Pengawas Obat dan Makanan; [reviewed 25 Oct 6; cited 2025 Jul 4]. Available from: https://registrasiobat.pom.go.id/files/assesment-reports/01766032524.pdf
  19. National Institute for Health and Care Excellence (NICE). Secukinumab for treating moderate to severe plaque psoriasis in children and young people [TA734]. 2021. Available from: https://www.nice.org.uk/guidance/ta734 [Accessed 4th July 2025].
  20. Kampylafka E, Simon D, d’Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation – Data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):1–9.
  21. Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: A multi-center, retrospective, 3-year study. Expert Opin Biol Ther. 2023;23(4):365–70.
  22. Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study. J Dermatol Treat. 2020;31(5):476–83.
  23. Momose M, Asahina A, Umezawa Y, Nakagawa H. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience. J Dermatol. 2018;45(3):318–21.
  24. Yildirim FE, Hapa FA. Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. J Dermatolog Treat. 2022;33(3):1531–7.
  25. Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: A real-life cohort study. Chin Med J (Engl). 2021;134(11):1324–8.
  26. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e9
  27. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):1–11.

Download

Share

COinS